Amplia Therapeutics Starts Phase 2b Trial of Narmafotinib for Pancreatic Cancer
Amplia Therapeutics has begun a Phase 2b study testing daily dosing of narmafotinib in newly diagnosed pancreatic cancer patients. The trial combines the drug with standard chemotherapy and will initially enroll 12 patients across Australian sites.
The Sydney Morning HeraldAmplia Therapeutics has launched a Phase 2b registration-enabling trial of narmafotinib in pancreatic cancer. The study will test continuous daily dosing at two potency levels combined with gemcitabine and Abraxane. The trial will enroll 12 newly diagnosed patients split into two cohorts of six.
Patient recruitment is scheduled to begin by Q4 2026 at three to four clinical sites in Australia, with safety and pharmacokinetic data expected in Q2 2027.
Narmafotinib targets Focal Adhesion Kinase (FAK), a protein that pancreatic cancer cells use to build protective scar tissue around tumors. The drug is intended to reduce this barrier so chemotherapy and the immune system can reach the cancer more effectively. The company previously reported final results from its 64-patient ACCENT trial in March. 1 months.
Therapeutics was founded in 2000 as Innate Immunotherapeutics and shifted focus to cancer drugs in 2018. It acquired narmafotinib through the purchase of Amplia Therapeutics that year and later changed its name and ASX ticker to ATX. The company has also begun a separate study with the Australia New Zealand Gynaecological Oncology Group to test narmafotinib with paclitaxel in 15 to 20 patients with advanced recurrent ovarian cancer.
Amplia is exploring combinations with KRAS inhibitors, which are under development for pancreatic cancer. Laboratory data presented in March showed narmafotinib blocked emergency survival pathways in pancreatic, lung, and ovarian cancer cells.
Key Facts
Story Timeline
3 events- March
Amplia released final data from the 64-patient ACCENT trial.
1 sourceThe Sydney Morning Herald - March
Laboratory data on narmafotinib and KRAS inhibitors were presented at an oncology conference in Los Angeles.
1 sourceThe Sydney Morning Herald - 2026
Amplia launched a Phase 2b trial of narmafotinib in pancreatic cancer.
1 sourceThe Sydney Morning Herald
Potential Impact
- 01
Safety and tolerability data from the trial will be available by Q2 2027.
- 02
Positive trial results could support further development of narmafotinib.
Transparency Panel
Related Stories
Los Angeles TimesEU Fines Temu €200 Million Over Unsafe Products
The European Commission imposed a €200 million fine on Chinese e-commerce platform Temu for failing to assess risks from illegal goods. The penalty is the second issued under the Digital Services Act.
Aggreko to Build Off-Grid Hybrid Plant for Eva Copper Mine
Global energy company Aggreko will construct Australia's largest off-grid renewable hybrid power facility at the Eva Copper Mine in North West Queensland. The 15-year project will supply 72 megawatts of power using solar, battery storage and thermal generation.
theyeshivaworld.comEU fines Temu more than $230 million over illegal product sales
The European Commission imposed a €200 million penalty on the Chinese e-commerce platform after finding consumers are very likely to encounter illegal items. Temu has until August 26 to submit a compliance plan or face further penalties.